Ascelia Pharma AB (publ) (ticker: ACE) was yesterday evening awarded the price for best Life Science company in Malmö at the city’s prestigious annual corporate awards (Malmö Näringslivsgala). The price award follows Ascelia Pharma’s work on developing novel drug candidates that fill a distinct unmet medical need.
“We are very pleased and honored by the award that emphasises our diligent work to develop novel drugs that improve the life expectancy and quality of life for people living with cancer. As communicated earlier, we have opened sites for patient enrolment in our registration-enabling Phase III study for our lead drug candidate Mangoral and expect sales launch in 2022 in the US. To ensure continued successful development, we are expanding our company in Malmö”, said Magnus Corfitzen, CEO of Ascelia Pharma.
For more information, please contact:
Magnus Corfitzen, CEO
Tel. 46 735 179 110
Mikael Widell, IR & Communications Manager
Tel: +46 703 11 99 60
About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.
Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.